In Brief

  • A clinical trial passes through phases, from small studies of safety to large comparisons with a control. Early results are often more striking than later ones.
  • Research volunteers are screened, prepared for weeks, and accompanied throughout. A result from that setting does not describe what happens anywhere else.
  • Ask of any finding who was studied, compared with what, for how long, what harms were counted, and who paid.

News of psychedelic research travels quickly and changes shape as it goes. A careful early study of a few dozen people becomes, by its third retelling, a cure. A single troubling case becomes, by its third retelling, proof of catastrophe. This volume offers a few plain tools for reading such news without being carried off in either direction. It makes no promises of its own; see How to Read This Library.

The Phases of a Trial

Most countries require a new medicine to pass through a sequence of studies before it may be approved. The names vary a little from place to place, but the pattern is broadly the same. Attested

Phase I
Small studies, often in healthy volunteers, chiefly to learn whether a substance is safe enough to study further and how the body handles it.
Phase II
Larger studies in people with a particular condition, to see whether there is a signal of benefit worth pursuing.
Phase III
Large trials, often at many sites, comparing the treatment with a control. Regulators usually require these before approval.
After approval
Continued watching for rare harms that appear only when many thousands of people have been treated.

Most psychedelic research so far has been in the first two phases, and only a few programs have reached the third. Attested A regulator may also give a promising treatment for a serious condition a special designation, sometimes called "breakthrough therapy," to speed its study. That is a judgment of promise and of priority, not a finding that the treatment works. Attested

Who Was Studied

Research volunteers are not a random sample of humanity. In the protocols we have read, everyone is screened before enrollment for current and past serious mental illness, and many people are excluded for their medicines, their health, or their family histories. Attested Those who remain spend weeks building trust with the study team before the session itself.

A result from people so chosen and so prepared tells us something real. It does not tell us what happens to a person who would have been screened out, or to anyone who takes the same substance without the screening, the preparation, and the company. See Before You Begin.

Some studies use healthy volunteers. Others are online surveys of people describing their own past experiences. Surveys can reach many thousands, but the people who choose to answer them are not typical, and memory is a generous editor.

Compared with What?

The strongest trials compare a treatment with something else, such as a placebo, another medicine, or a much smaller amount, and keep both the participants and the people measuring the results unaware of who received which. Attested Psychedelic research has an old difficulty here. Most participants can tell within the hour whether they have received the active substance, and so can those sitting with them, which makes a fair comparison hard to keep. Attested That difficulty was among the concerns raised when MDMA-assisted therapy was turned down in 2024. Attested See The Second Spring.

Remember too that in these trials the substance never arrives alone. It comes wrapped in weeks of preparation, two guides, a carefully designed room, chosen music, and sessions afterward. Attested When such a study reports benefit, it is the whole package that has been tested, and no one can yet say how much of the good belongs to each part. Debated See The Living Room Protocol.

How Long, and How Many?

Researchers in the field have reported that a single supervised session can be followed by lasting improvement in anxiety, depression, and wellbeing. Attested How long such benefits last, and for how many people, is still being measured. Debated Ask how many people took part and how long they were followed. A study of thirty people followed for six weeks is a beginning, not an answer.

In medicine generally, the first small studies of a new treatment often report larger effects than the bigger studies that follow them. Psychedelic research has no exemption from that rule.

Were Harms Counted?

A study that reports benefits and says little about harm is half a study. Researchers within the field have argued that harms in psychedelic therapies need to be assessed more carefully and more consistently, and have proposed a framework for doing so. Attested

Look for what was asked, and for how long. Some difficulties arrive days or weeks after a session, and some research centers now run clinics for people who struggle afterward. Attested A trial that looked for harms only on the day itself may have missed them.

Who Paid, and Who Is Speaking?

Look for who funded a study and who is describing it. A company whose value depends on the result, a nonprofit raising money, a clinic seeking patients, a journalist seeking readers, and an independent reviewer may all describe the same paper differently.

Listen to the adjectives. Words like "groundbreaking," "revolutionary," "the world's largest," and "the leading" are the language of announcements and not of evidence. We met every one of them in the public pages we read for this shelf, and some came from organizations we respect. A claim an institution makes about itself remains an advertisement until someone else confirms it.

If You Are Thinking of Volunteering

Public registries of clinical trials list studies by substance and by place, with their requirements for joining, and research centers post their own studies and invite volunteers. Attested If you are considering taking part:

  • Read the requirements closely, and answer every screening question honestly. The questions exist for your safety.
  • Expect many visits over weeks or months. Most trials prefer people who live within easy reach of the site. Attested
  • Remember that a trial exists to answer a question, not to treat you. You may receive the comparison instead of the substance.
  • Talk with your own doctor first, and do not stop or change any medicine without that doctor's guidance.
  • Read the consent form slowly, and keep a copy. You may leave a trial at any time.

Seven Questions to Carry

  1. What phase was this, and how many people took part?
  2. Who was included, and who was screened out?
  3. What was it compared with, and could participants tell which they had received?
  4. What came with the substance: preparation, therapy, music, follow-up?
  5. How long were people followed afterward?
  6. What harms were looked for, and when, and what was found?
  7. Who paid for the study, and who is telling me about it?

If a report cannot answer these, hold it lightly. If it can, and the answers are good, let yourself be encouraged. Encouragement is still not a promise.

About the Keeper

Tobias Halloway, Keeper of the Record

Tobias is a folklorist and former parish archivist with a patient love for footnotes. He tends the history shelf and sets the three seals on every historical claim in the library.